In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing ...

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire ...

Giuseppe Accogli became the Group CEO of Chiesi Pharmaceuticals in 2023. With a 25-year career in the med-tech industry, he ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share in cash, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are ...

JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to ...

From 2019-2023, North Carolina increased the number of life sciences business establishments by 43%. To learn more in the ...

The major averages opened the season broadly lower, with the Dow and S&P 500 continuing yesterday’s declines amid ongoing uncertainty around ...